{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:38:45Z","timestamp":1794749925854,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41591-022-02183-6","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T12:03:30Z","timestamp":1675685010000},"page":"467-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Prevalence of smoldering multiple myeloma based on nationwide screening"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5017-3530","authenticated-orcid":false,"given":"Sigr\u00fan","family":"Thorsteinsd\u00f3ttir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4710-0781","authenticated-orcid":false,"given":"Gauti K.","family":"G\u00edslason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7998-5433","authenticated-orcid":false,"given":"Thor","family":"Aspelund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e6mundur","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-1166","authenticated-orcid":false,"given":"J\u00f3n \u00de\u00f3rir","family":"\u00d3skarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gu\u00f0r\u00fan \u00c1","family":"Sigur\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sd\u00eds R.","family":"\u00de\u00f3r\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynjar","family":"Vi\u00f0arsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1ll T.","family":"\u00d6nundarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarni A.","family":"Agnarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margr\u00e9t","family":"Sigur\u00f0ard\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"\u00deorsteinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cdsleifur","family":"\u00d3lafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u00edas","family":"Ey\u00fe\u00f3rsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1sbj\u00f6rn","family":"J\u00f3nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G. M.","family":"Durie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur J.","family":"L\u00f6ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-4839","authenticated-orcid":false,"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigur\u00f0ur Y.","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"2183_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","volume":"302","author":"RA Kyle","year":"1980","unstructured":"Kyle, R. A. & Greipp, P. R. Smoldering multiple myeloma. N. Engl. J. Med. 302, 1347\u20131349 (1980).","journal-title":"N. Engl. J. Med."},{"key":"2183_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"2183_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"2183_CR4","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1056\/NEJMc1310911","volume":"369","author":"SY Kristinsson","year":"2013","unstructured":"Kristinsson, S. Y., Holmberg, E. & Blimark, C. Treatment for high-risk smoldering myeloma. N. Engl. J. Med. 369, 1762\u20131763 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2183_CR5","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan, A. J. et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 4, 1221\u20131227 (2018).","journal-title":"JAMA Oncol."},{"key":"2183_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle, R. A. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24, 1121\u20131127 (2010).","journal-title":"Leukemia"},{"key":"2183_CR7","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586\u20132592 (2007).","journal-title":"Blood"},{"key":"2183_CR8","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785\u2013789 (2008).","journal-title":"Blood"},{"key":"2183_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"M-V Mateos","year":"2020","unstructured":"Mateos, M.-V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 10, 102 (2020).","journal-title":"Blood Cancer J."},{"key":"2183_CR10","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","volume":"125","author":"SV Rajkumar","year":"2015","unstructured":"Rajkumar, S. V., Landgren, O. & Mateos, M.-V. Smoldering multiple myeloma. Blood 125, 3069\u20133075 (2015).","journal-title":"Blood"},{"key":"2183_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4","volume":"8","author":"A Lakshman","year":"2018","unstructured":"Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 8, 59 (2018).","journal-title":"Blood Cancer J."},{"key":"2183_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1300439","volume":"369","author":"M-V Mateos","year":"2013","unstructured":"Mateos, M.-V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438\u2013447 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2183_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","volume":"17","author":"M-V Mateos","year":"2016","unstructured":"Mateos, M.-V. et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 17, 1127\u20131136 (2016).","journal-title":"Lancet Oncol."},{"key":"2183_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1200\/JCO.19.01740","volume":"38","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126\u20131137 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2183_CR15","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar, S. K. et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 18, 1685\u20131717 (2020).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"2183_CR16","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.1016\/S2352-3026(21)00335-5","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial, S., Rajkumar, S. V. & Mateos, M. V. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. Lancet Haematol. 9, e162\u2013e165 (2022).","journal-title":"Lancet Haematol."},{"key":"2183_CR17","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","volume":"1","author":"EE Sigurdardottir","year":"2015","unstructured":"Sigurdardottir, E. E. et al. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. JAMA Oncol. 1, 168\u2013174 (2015).","journal-title":"JAMA Oncol."},{"key":"2183_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.clml.2014.09.004","volume":"15","author":"RS Go","year":"2015","unstructured":"Go, R. S., Gundrum, J. D. & Neuner, J. M. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.Clin. Lymphoma Myeloma Leuk. 15, 177\u2013186.e4 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2183_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson, S. et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 11, 94 (2021).","journal-title":"Blood Cancer J."},{"key":"2183_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/ejh.12728","volume":"97","author":"R S\u00f8rrig","year":"2016","unstructured":"S\u00f8rrig, R. et al. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. Eur. J. Haematol. 97, 303\u2013309 (2016).","journal-title":"Eur. J. Haematol."},{"key":"2183_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","volume":"378","author":"RA Kyle","year":"2018","unstructured":"Kyle, R. A. et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 378, 241\u2013249 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2183_CR22","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","volume":"37","author":"JS Miguel","year":"2019","unstructured":"Miguel, J. S. et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J. Clin. Oncol. 37, 8000 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2183_CR23","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/jamaoncol.2020.5585","volume":"7","author":"E Hill","year":"2021","unstructured":"Hill, E. et al. Assessment of discordance among smoldering multiple myeloma risk models. JAMA Oncol. 7, 132\u2013134 (2021).","journal-title":"JAMA Oncol."},{"key":"2183_CR24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jamaoncol.2019.4659","volume":"6","author":"F Maura","year":"2019","unstructured":"Maura, F. et al. Moving from cancer burden to cancer genomics for smoldering myeloma: a review. JAMA Oncol. 6, 425\u2013432 (2019).","journal-title":"JAMA Oncol."},{"key":"2183_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.CCR-20-1395","volume":"27","author":"F Maura","year":"2021","unstructured":"Maura, F., Landgren, O. & Morgan, G. J. Designing evolutionary based interception strategies to block the transition from precursor phases to multiple myeloma. Clin. Cancer Res. 27, 15\u201323 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2183_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/hematology.2021000303","volume":"2021","author":"O Landgren","year":"2021","unstructured":"Landgren, O. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. Hematology Am. Soc. Hematol. Educ. Program 2021, 662\u2013672 (2021).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"2183_CR27","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","volume":"82","author":"O Landgren","year":"2007","unstructured":"Landgren, O. et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin. Proc. 82, 1468\u20131473 (2007).","journal-title":"Mayo Clin. Proc."},{"key":"2183_CR28","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0025-6196(11)61090-2","volume":"82","author":"M Iwanaga","year":"2007","unstructured":"Iwanaga, M., Tagawa, M., Tsukasaki, K., Kamihira, S. & Tomonaga, M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin. Proc. 82, 1474\u20131479 (2007).","journal-title":"Mayo Clin. Proc."},{"key":"2183_CR29","first-page":"930","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos, M. A., Kastritis, E. & Terpos, E. Non-secretory myeloma: one, two, or more entities? Oncology 27, 930\u2013932 (2013).","journal-title":"Oncology"},{"key":"2183_CR30","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1080\/10428194.2021.1938032","volume":"62","author":"GR Mohyuddin","year":"2021","unstructured":"Mohyuddin, G. R., Ouchveridze, E., Goodman, A. & Prasad, V. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. Leuk. Lymphoma 62, 2793\u20132795 (2021).","journal-title":"Leuk. Lymphoma"},{"key":"2183_CR31","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.3324\/haematol.2021.278519","volume":"106","author":"P Musto","year":"2021","unstructured":"Musto, P. et al. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Haematologica 106, 2799\u20132812 (2021).","journal-title":"Haematologica"},{"key":"2183_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PPO.0000000000000350","volume":"25","author":"P Kapoor","year":"2019","unstructured":"Kapoor, P. & Rajkumar, S. V. Smoldering multiple myeloma: to treat or not to treat. Cancer J. 25, 65\u201371 (2019).","journal-title":"Cancer J."},{"key":"2183_CR33","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","volume":"31","author":"J Flores-Montero","year":"2017","unstructured":"Flores-Montero, J. et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia 31, 2094\u20132103 (2017).","journal-title":"Leukemia"}],"updated-by":[{"DOI":"10.1038\/s41591-023-02308-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,3,20]],"date-time":"2023-03-20T00:00:00Z","timestamp":1679270400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02183-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02183-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T03:07:46Z","timestamp":1679368066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-02183-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-02183-6","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-023-02308-5","URL":"https:\/\/doi.org\/10.1038\/s41591-023-02308-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.B. and S.H. are currently employed by The Binding Site. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}